Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Merck
Boehringer Ingelheim
Baxter
McKinsey

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019717

See Plans and Pricing

« Back to Dashboard

NDA 019717 describes HUMULIN 70/30 PEN, which is a drug marketed by Lilly and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the HUMULIN 70/30 PEN profile page.

The generic ingredient in HUMULIN 70/30 PEN is insulin recombinant human; insulin susp isophane recombinant human. There are forty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.
Summary for 019717
Suppliers and Packaging for NDA: 019717
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HUMULIN 70/30 insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019717 NDA Eli Lilly and Company 0002-8715 0002-8715-01 1 VIAL, MULTI-DOSE in 1 CARTON (0002-8715-01) > 10 mL in 1 VIAL, MULTI-DOSE
HUMULIN 70/30 insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019717 NDA Eli Lilly and Company 0002-8715 0002-8715-17 1 VIAL, MULTI-DOSE in 1 CARTON (0002-8715-17) > 3 mL in 1 VIAL, MULTI-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:INJECTABLE;INJECTIONStrength30 UNITS/ML;70 UNITS/ML
Approval Date:Apr 25, 1989TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Aug 9, 2024Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:OTCDosage:INJECTABLE;INJECTIONStrength30 UNITS/ML;70 UNITS/ML
Approval Date:Aug 6, 1998TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Aug 9, 2024Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKinsey
Mallinckrodt
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.